Table 1.
Demographic characteristics of patients treated with and without nCRT.
| Before propensity score matching | After propensity score matching | |||||
|---|---|---|---|---|---|---|
| Open (n = 147) |
MIS (n = 166) |
p | Open (n = 118) |
MIS (n = 118) |
p | |
| Age (years, median ± (SD) | 58 ± 12 | 57 ± 11 | 0.770 | 58 ± 12 | 58 ± 11 | 0.879 |
| Sex, n (%) | 0.552 | 0.893 | ||||
| Male | 89 (60.5) | 95 (57.2) | 74 (62.7) | 73 (61.9) | ||
| Female | 58 (39.5) | 71 (42.8) | 44 (37.3) | 45 (38.1) | ||
| BMI (kg/m2) | 23.4 ± 3.2 | 23.3 ± 3.5 | 0.677 | 23.4 ± 2.8 | 23.3 ± 3.1 | 0.700 |
| ASA score, n (%) | 1.000 | 1.000 | ||||
| < 3 | 146 (99.3) | 165 (99.4) | 117 (99.2) | 117 (99.2) | ||
| ≥ 3 | 1 (0.7) | 1 (0.6) | 1 (0.8) | 1 (0.8) | ||
| Underlying, n (%) | 68 (46.3) | 77 (46.4) | 0.982 | 59 (50.0) | 50 (50.0) | 1.000 |
| HTN | 49 (33.3) | 53 (31.9) | 0.791 | 42 (35.6) | 41 (34.7) | 0.892 |
| DM | 20 (13.6) | 27 (16.3) | 0.511 | 17 (14.4) | 20 (16.9) | 0.591 |
| IHD | 7 (4.8) | 4 (2.4) | 0.259 | 6 (5.1) | 4 (3.4) | 0.518 |
| COPD | 10 (6.8) | 4 (2.4) | 0.061 | 9 (7.6) | 4 (3.4) | 0.154 |
| Operative period | < 0.001 | < 0.001 | ||||
| 2000–2008 | 58 (39.5) | 7 (4.2) | 47 (39.8) | 5 (4.2) | ||
| 2009–2014 | 89 (60.5) | 159 (95.8) | 71 (60.2) | 113 (95.8) | ||
| Preoperative CEA (ng/mL) | 2.8 ± 5.7 | 2.9 ± 6.7 | 0.885 | 3.1 ± 5.9 | 2.8 ± 6.3 | 0.697 |
| Preoperative CA19-9 (ng/mL) | 13.4 ± 16.2 | 13.1 ± 16.0 | 0.881 | 12.2 ± 7.2 | 13.7 ± 17.1 | 0.361 |
| Tumor distance from AV (cm) | 3.2 ± 1.5 | 3.0 ± 1.4 | 0.272 | 2.8 ± 1.7 | 2.9 ± 1.5 | 0.528 |
| Neoadjuvant CCRT, n (%) | 71 (48.3) | 42 (25.3) | < 0.001 | 42 (35.6) | 42 (35.6) | 1.000 |
| Adjuvant treatment, n (%) | 104 (70.7) | 93 (56.0) | 0.007 | 80 (67.8) | 78 (66.1) | 0.782 |
nCRT neoadjuvant chemoradiotherapy, MIS minimally invasive surgery, BMI body mass index, ASA American society of anesthesiologists, HTN hypertension, DM diabetes mellitus, IHD ischemic heart disease, COPD chronic obstructive pulmonary disease, CEA carcinoembryonic antigen, AV anal verge.